Durvalumab, on the other hand, is a PD‐L1 inhibitor that blocks the interaction between PD‐L1 and PD‐1, allowing T cells to recognize and kill tumor cells (Chen et al. 2023; Liu et al. 2021). Here, CD274 is linked to neoplasm.